scispace - formally typeset
Z

Ziyi Song

Researcher at Albert Einstein College of Medicine

Publications -  8
Citations -  239

Ziyi Song is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 2, co-authored 2 publications receiving 113 citations.

Papers
More filters
Journal ArticleDOI

Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues

TL;DR: This review will update the current knowledge of DNL in white and brown adipose tissues with the focus on transcriptional, post-translational, and central regulation of D NL.
Journal ArticleDOI

Lipogenic SREBP-1a/c transcription factors activate expression of the iron regulator hepcidin, revealing cross-talk between lipid and iron metabolisms

TL;DR: Results indicate that the SREBP-1a/c transcription regulators activate hepcidin expression and thereby contribute to the control of mammalian iron metabolism.
Journal ArticleDOI

Maternal High-Fructose Intake Activates Myogenic Program in Fetal Brown Fat and Predisposes Offspring to Diet-Induced Metabolic Dysfunctions in Adulthood

TL;DR: It is shown that maternal consumption of 20% fructose water during pregnancy does not alter the metabolic balance of offspring with a chow diet, but predisposes them to obesity, fatty liver, and insulin resistance when challenged by a high-fat diet.
Journal ArticleDOI

A New lncRNA, lnc-LLMA, Regulates Lipid Metabolism in Pig Hepatocytes.

TL;DR: This study found a highly expressed lncRNA in the liver of Duroc pigs, which was enriched in the nucleus and demonstrated that this novel lnc RNA was closely related to lipid metabolism and affected lipid transport and mitochondrial function through MTTP and GYS2.
Journal ArticleDOI

Discovery of New Inhibitors of eEF2K from Traditional Chinese Medicine Based on In Silico Screening and In Vitro Experimental Validation

TL;DR: Together, by integrating in silico screening and in vitro biochemical studies, Oleuropein and Rhoifolin were revealed as novel e EF2K inhibitors, which will shed new lights for eEF2K-targeting drug development and anticancer therapy.